Details of the Drug
General Information of Drug (ID: DMEC1I9)
| Drug Name | Zn2+ | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
                        zinc ion; Zinc cation; zinc(2+); Zinc, ion (Zn2+); 23713-49-7; Zn(II); Velmanase Alfa; UNII-13S1S8SF37; Zinc (II) ion; zinc(2+) ion; Zinc (II); Velmanase Alfa [INN]; Zn+2; CHEBI:29105; Zn(2+); 13S1S8SF37; 9025-42-7; Microheterogeneityzinc Ion; alpha-Mannanase; Zinc ions; alpha-Mannosidase; Zinc(2+)ions; Mannosidase, alpha-; alpha-Mannopyranosidase; Zinc 2+; Rhlaman; dietary zinc; UNII-M91TG242P2; Zinc dication; zinc(II) cation; Zinc divalent ion; alpha-Mannosidase recombinant human; Recombinant Human Alpha-mannosidase
                        
                     | ||||||||||||||||||||||
| Indication | 
 | ||||||||||||||||||||||
| Affected Organisms | Humans and other mammals | ||||||||||||||||||||||
| ATC Code | |||||||||||||||||||||||
| Drug Type | Small molecular drug | ||||||||||||||||||||||
| Structure |  | ||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight | 65.4 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
| Rotatable Bond Count | 0 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count | 0 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count | 0 | ||||||||||||||||||||||
| Chemical Identifiers | 
 | ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
|  Drug Therapeutic Target (DTT) | 
 | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
References
